U.S. Markets closed
  • S&P Futures

    4,108.25
    -14.75 (-0.36%)
     
  • Dow Futures

    33,877.00
    -119.00 (-0.35%)
     
  • Nasdaq Futures

    13,162.50
    -49.50 (-0.37%)
     
  • Russell 2000 Futures

    2,200.90
    -7.00 (-0.32%)
     
  • Crude Oil

    64.70
    -0.79 (-1.21%)
     
  • Gold

    1,869.50
    +1.50 (+0.08%)
     
  • Silver

    28.14
    -0.19 (-0.68%)
     
  • EUR/USD

    1.2234
    +0.0007 (+0.0612%)
     
  • 10-Yr Bond

    1.6420
    +0.0020 (+0.12%)
     
  • Vix

    21.34
    +1.62 (+8.22%)
     
  • GBP/USD

    1.4189
    +0.0002 (+0.0113%)
     
  • USD/JPY

    108.9330
    +0.0430 (+0.0395%)
     
  • BTC-USD

    40,634.63
    -4,199.12 (-9.37%)
     
  • CMC Crypto 200

    1,123.09
    -130.05 (-10.38%)
     
  • FTSE 100

    7,034.24
    +1.39 (+0.02%)
     
  • Nikkei 225

    27,984.77
    -422.07 (-1.49%)
     

Becton, Dickinson: Q1 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Becton, Dickinson (NYSE:BDX) moved higher by 0.0% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share rose 71.70% over the past year to $4.55, which beat the estimate of $3.11.

Revenue of $5,315,000,000 higher by 25.80% from the same period last year, which beat the estimate of $4,880,000,000.

Guidance

The upcoming fiscal year's EPS expected to be between $12.75 and $12.85.

The upcoming fiscal year's revenue expected to be between $19,171,000,000 and $19,513,000,000.

Details Of The Call

Date: Feb 04, 2021

View more earnings on BDX

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/isdudxg2

Price Action

Company's 52-week high was at $286.72

Company's 52-week low was at $197.75

Price action over last quarter: Up 10.22%

Company Description

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.